Related Experiment Video
Updated: Mar 3, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Targeting cellular source-specific CXCL9 signaling for immunotherapy in oral squamous cell carcinoma
Miao Qiu1, Ling Wang2, Honglin Tang3
1Department of Pharmacy, Shenzhen Stomatology Hospital (Pingshan) of Southern Medical University, Shenzhen, China.
Abstract:
Oral squamous cell carcinoma (OSCC) remains a clinical challenge due to its high recurrence, metastatic potential, and limited responsiveness to current immunotherapies. Within the tumor microenvironment (TME), the C-X-C motif chemokine ligand 9 (CXCL9) plays a pivotal yet paradoxical role, functioning as both an anti-tumor effector and a tumor-promoting factor depending on its cellular origin. This review proposes that the function of CXCL9 is not intrinsic but dictated by the interplay among its cellular source, microenvironmental context, and receptor-expressing cells. We delineate how this tripartite crosstalk influences immune checkpoint blockade (ICB) outcomes through mechanisms such as T-cell suppression, regulatory T cells recruitment, and PD-L1 upregulation. Myeloid cell-derived CXCL9 generally mediates anti-tumor immunity by recruiting cytotoxic lymphocytes, whereas CXCL9 produced by stromal cells like cancer-associated fibroblasts often contributes to metastasis and immune evasion. Given this complexity and unique immunosuppressive and fibrotic properties of OSCC, we argue that simply augmenting or blocking CXCL9 is insufficient. Instead, overcoming ICB resistance in OSCC requires a precision strategy focused on targeting cell-specific CXCL9 signaling. Ultimately, dissecting and therapeutically navigating the source-specific CXCL9 network is essential to transform the OSCC TME and improve clinical outcomes.
Insights
The role of C-X-C motif chemokine ligand 9 (CXCL9) in oral squamous cell carcinoma (OSCC) is complex, acting as both anti-tumor and pro-tumorigenic depending on its source. Targeting cell-specific CXCL9 signaling is key to overcoming immunotherapy resistance in OSCC.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Oral squamous cell carcinoma (OSCC) presents significant clinical challenges, including high recurrence rates and resistance to immunotherapy.
- The tumor microenvironment (TME) plays a critical role in OSCC progression and treatment response.
- C-X-C motif chemokine ligand 9 (CXCL9) exhibits paradoxical functions within the TME, influencing anti-tumor immunity and tumor promotion.
Purpose of the Study:
- To review the multifaceted role of CXCL9 in the OSCC tumor microenvironment.
- To elucidate how the cellular origin and microenvironmental context dictate CXCL9 function.
- To propose strategies for overcoming immune checkpoint blockade (ICB) resistance in OSCC by targeting cell-specific CXCL9 signaling.
Main Methods:
- Literature review and synthesis of existing research on CXCL9 in OSCC.
- Analysis of the interplay between CXCL9 source, microenvironment, and receptor-expressing cells.
- Delineation of mechanisms by which CXCL9 influences T-cell responses, regulatory T cells, and PD-L1 expression.
Main Results:
- CXCL9 function is context-dependent, not intrinsic.
- Myeloid-derived CXCL9 generally promotes anti-tumor immunity by recruiting cytotoxic lymphocytes.
- Stromal cell-derived CXCL9, particularly from cancer-associated fibroblasts, often facilitates metastasis and immune evasion.
Conclusions:
- Simple augmentation or blockade of CXCL9 is insufficient for treating OSCC.
- A precision medicine approach targeting cell-specific CXCL9 signaling is required to overcome ICB resistance.
- Understanding and therapeutically manipulating the source-specific CXCL9 network is crucial for improving OSCC outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy